Ingen Shows a New, Strong Future While Completing Year-End Financials

YUCAIPA, Calif., May 27, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink
Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8 Billion
global Respiratory Markets for the growing ageing population and emerging
markets for Home (DME), Hospital and Aviation Industries, announced today that
the company has positioned itself with a strong future while they near their
year-end on May 31, 2009.

The company accountants have initiated the preparation of the financial and
disclosure statements for an early filing in June-2009. "Our accounting team has
already begun the financial preparation for filing our May 31, 2009 Year-End
statements and disclosure. This will be filed on or before the end of
June-2009," stated Thomas J. Neavitt, Chief Financial officer of Ingen
Technologies.

The company continued to make strong progress during the past few months while
strengthening their intellectual property, export sales, and global
distribution/OEM partnerships while introducing their new respiratory product
line.

Specifically, Ingen was recently notified of the issuance of their Oxyview
patent in China. Foreign patents have been pending in the European Communities
and Japan for 2 years, and the company has recently been notified that both
entities have recently made a Request for Examination to bring closer the
issuance of these patents. The company already owns several issued U.S. patents
and trademarks. Further, the company recently announced the agreement with
Emergo Global Consulting group regarding the preparations of the International
Standards Organization (ISO) and CE mark certifications required for the export
sale and marketing of Oxyview. Ingen received registration and classification
from the Food & Drug Administration for Oxyview in 2007, and was granted a
device manufacturing license with the California Department of Public Health.
Both the FDA registration and DHS-license will facilitate the ISO and CE Mark
certifications.

Most recently, the company announced on May 19, 2009 the distribution of their
new Oxyview-Cannula product and the agreement they have with Legend Medical
Devices to include and package their Legend-MD cannula with Ingen's Oxyview flow
meter. The company intends to offer the new disposable Oxyview-Cannula at the
same price as the leading competitor's price. This will offer patients an
improved cannula for oxygen therapy. The Oxyview-Cannula will be the first
cannula of its kind offered with a pneumatic gravity-independent flow meter
already included.

"Our Board of Directors, Management and professional staff have strived to make
this company successful. Despite the economic turmoil that we faced at the time
we began to market our new respiratory products in 2008, we have made great
accomplishments in the past several months that will point Ingen in a direction
of strong earnings and a more realistic market value. The global medical
community has become aggressively responsive to the importance of Oxyview and
the economical and therapeutic advantages it can offer to our ailing COPD
patients worldwide. The company will experience dramatic improvements during our
upcoming new year," stated Scott R. Sand, Chief Executive Officer and Chairman
of the Board.

About Oxyview:

Oxyview is a proprietary medical device with US issued patents that stands alone
in an increasing patient home oxygen therapy market while there are 23 million
patients diagnosed with chronic obstructive pulmonary disease (COPD) in the
United States, according to the World Health Organization, and another 12
million patients that are undiagnosed in the US. COPD is the fifth leading cause
of death in the US and there are 600 million COPD patients worldwide where in
most cases, COPD is either the first or second leading cause of death in other
countries. The majority of COPD patients require continued home oxygen therapy,
which includes all of the required equipment supplied by the home (DME)
provider. With the new regulations for oxygen reimbursement in the US, the home
(DME) providers need to cut costs to stay in business. Oxyview provides a
substantial savings as a result of decreasing the number of service calls for
the home (DME) provider. Oxyview is a pneumatic metering device that displays
oxygen flow near the patient. The Oxyview flow meter easily and quickly installs
on to the oxygen tubing nearest the patient where oxygen flow matters the most.
Without the Oxyview, patients cannot confirm oxygen flow, and as a result there
is an increase in anxiety and the patient calls the home (DME) provider with
concerns. Oxyview also allows the home (DME) provider to trouble-shoot other
equipment problems over the telephone which eliminates an on-site visit with the
patient. More important, the Oxyview provides the patient with more assurance
that they are receiving adequate and prescribed oxygen flow. The Oxyview cost
less than a single service call.

www.ingen-tech.com

The Ingen Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes
forward-looking statements. While these statements are made to convey to the
public the company's progress, business opportunities and growth prospects,
readers are cautioned that such forward-looking statements represent
management's opinion. Whereas management believes such representations to be
true and accurate based on information and data available to the company at this
time, actual results may differ materially from those described. The company's
operations and business prospects are always subject to risk and uncertainties.
Important factors that may cause actual results to differ are and will be set
forth in the company's periodic filings with the U.S. Securities and Exchange
Commission.

-0-
CONTACT: Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
www.INGEN-TECH.COM